NASDAQ:MGRX Mangoceuticals 7/28/2023 Earnings Report $1.92 -0.11 (-5.42%) Closing price 04:00 PM EasternExtended Trading$1.92 0.00 (0.00%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Mangoceuticals EPS ResultsActual EPS-$31.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMangoceuticals Revenue ResultsActual Revenue$0.14 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMangoceuticals Announcement DetailsQuarterDate7/28/2023TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Mangoceuticals Earnings HeadlinesMangoceuticals Strengthens Position with Equity TransactionsJune 10, 2025 | tipranks.comMangoceuticals files to sell 4.46M shares of common stock by selling shareholdersMay 30, 2025 | msn.comMost Americans have no idea this plan exists...A Dollar Crash Is Coming - Here's When It Could Happen Already in 2025, the U.S. dollar has lost more value than in ANY year since Lehman's collapse. Meanwhile, bonds are falling... gold and silver are soaring... and bitcoin has risen over $100,000. Now, one analyst who predicted the 2008 crisis and recommended shorting Lehman for an 82% return in just five months explains why you need to get OUT of cash and exactly where to move your money instead.June 16, 2025 | Stansberry Research (Ad)Mangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 29, 2025 | finanznachrichten.deMangoceuticals, Inc. Reports 100% Survival Rates in Field Studies of MGX-0024 for Poultry Respiratory DiseasesMay 29, 2025 | nasdaq.comMangoceuticals shares results from field studies on MGX-0024May 29, 2025 | finance.yahoo.comSee More Mangoceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email. Email Address About MangoceuticalsMangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.View Mangoceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
